Pharmacology Quiz: Neuropathic Pain Agents
20 questions · exam conditions
0:00
Neuropathic Pain AgentsQuestion 1 of 20

A 68-year-old male with a history of ischemic heart disease (Q-wave abnormalities on EKG), benign prostatic hyperplasia, and painful diabetic neuropathy is being considered for pharmacotherapy. His current medications include metformin, lisinopril, and aspirin. Which of the following agents is most appropriate to avoid due to the patient's comorbidities?

Gabapentin
Duloxetine
Amitriptyline
Pregabalin
← Back to quizzes

Pharmacology Quiz

Pharmacology Quiz: Neuropathic Pain Agents

Practice Neuropathic Pain Agents in Pharmacology with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.

What this quiz covers

This quiz focuses on Neuropathic Pain Agents, giving you a quick way to practice the rules, question types, and explanations that matter most for Pharmacology.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

All questions

Question 1

A 68-year-old male with a history of ischemic heart disease (Q-wave abnormalities on EKG), benign prostatic hyperplasia, and painful diabetic neuropathy is being considered for pharmacotherapy. His current medications include metformin, lisinopril, and aspirin. Which of the following agents is most appropriate to avoid due to the patient's comorbidities?

  1. Gabapentin
  2. Duloxetine
  3. Amitriptyline (correct answer)
  4. Pregabalin
Explanation: Amitriptyline, a tricyclic antidepressant (TCA), should be avoided. TCAs have significant anticholinergic properties that can worsen benign prostatic hyperplasia, leading to urinary retention. Furthermore, they can cause cardiac conduction abnormalities (e.g., QT prolongation) and are relatively contraindicated in patients with pre-existing heart disease. Gabapentin (A) and pregabalin (D) lack these effects. Duloxetine (B), an SNRI, has a much lower anticholinergic and cardiotoxic potential than TCAs, making it a safer alternative in this patient.

Question 2

A patient with painful diabetic neuropathy and comorbid hypertension is managed with lisinopril and hydrochlorothiazide. The physician adds venlafaxine for the neuropathy. Which of the following parameters is most important to monitor after initiating venlafaxine in this patient?

  1. Serum creatinine
  2. Blood pressure (correct answer)
  3. Liver function tests
  4. Serum sodium
Explanation: Venlafaxine, an SNRI, can cause a dose-dependent increase in blood pressure due to its inhibition of norepinephrine reuptake. In a patient with pre-existing hypertension, it is crucial to monitor blood pressure closely after initiation and with each dose increase. While SNRIs can rarely cause hyponatremia (D) or hepatotoxicity (C), and renal function (A) is always good to monitor, the most common and predictable adverse effect related to the patient's comorbidity is an elevation in blood pressure.

Question 3

A patient with diabetic neuropathy and comorbid anxiety is being considered for treatment. Which of the following agents offers an evidence-based benefit for both conditions through a single mechanism of action?

  1. Venlafaxine, by inhibiting the reuptake of serotonin and norepinephrine. (correct answer)
  2. Pregabalin, by reducing the release of both glutamate and norepinephrine.
  3. Amitriptyline, by blocking muscarinic receptors and sodium channels.
  4. Gabapentin, by directly agonizing GABA-B receptors in the amygdala and spinal cord.
Explanation: When you encounter questions about dual-indication medications, focus on identifying drugs with well-established mechanisms that address both conditions through the same pathway. This tests your understanding of how pharmacological mechanisms can provide therapeutic benefits across different disease states. Venlafaxine (A) is correct because it's a serotonin-norepinephrine reuptake inhibitor (SNRI) with robust evidence for treating both diabetic neuropathy and anxiety through this single mechanism. The enhanced norepinephrine signaling modulates descending pain pathways to reduce neuropathic pain, while increased serotonin and norepinephrine availability treats anxiety. This dual benefit through one mechanism makes it an ideal choice for comorbid conditions. Pregabalin (B) is wrong because while it does treat both conditions effectively, it doesn't reduce norepinephrine release—it actually blocks voltage-gated calcium channels to decrease excitatory neurotransmitter release, including glutamate. The mechanism described is inaccurate. Amitriptyline (C) is incorrect because although it can help both conditions, it works through multiple mechanisms (not a single one as the question specifies). Its benefits come from various actions including norepinephrine reuptake inhibition, sodium channel blockade, and anticholinergic effects—not just the two mechanisms listed. Gabapentin (D) is wrong on multiple levels. While it treats neuropathic pain, it has limited evidence for anxiety disorders. Additionally, it doesn't directly agonize GABA-B receptors—it binds to voltage-gated calcium channel subunits. Remember: SNRIs like venlafaxine and duloxetine are your go-to dual-indication drugs for neuropathic pain plus mood/anxiety disorders. Focus on learning drugs with clear, single mechanisms that provide multiple therapeutic benefits.

Question 4

The analgesic effects of tricyclic antidepressants (TCAs) in neuropathic pain are thought to be distinct from their antidepressant effects. Which of the following observations best supports this distinction?

  1. The doses required for analgesia are typically much higher than those used for depression.
  2. Analgesia is primarily mediated by serotonin reuptake inhibition, while antidepressant effects are from norepinephrine.
  3. Only TCAs with potent antihistaminic properties, such as doxepin, demonstrate significant analgesic activity.
  4. The onset of analgesia is often more rapid (days to a week) than the onset of antidepressant effects (weeks). (correct answer)
Explanation: When you encounter questions about dual mechanisms of psychoactive drugs, focus on how different therapeutic effects can emerge through distinct pathways and timelines, even from the same medication. The key evidence supporting separate mechanisms for TCA analgesia versus antidepressant effects is the dramatic difference in onset timing. Analgesic effects from TCAs typically appear within days to one week of starting treatment, while antidepressant effects require several weeks to manifest. This temporal separation strongly suggests different underlying mechanisms are responsible for each therapeutic effect. Choice A is incorrect because analgesic doses are actually typically lower than antidepressant doses, not higher. This lower dose requirement further supports the distinct mechanism hypothesis. Choice B reverses the actual mechanisms - both analgesic and antidepressant effects involve multiple neurotransmitter systems, but the analgesic effects are thought to involve enhanced descending pain inhibition through both serotonin and norepinephrine pathways. Choice C is wrong because analgesic activity isn't limited to TCAs with strong antihistaminic properties; many TCAs demonstrate pain relief regardless of their histamine receptor affinity. The rapid onset of analgesia compared to the delayed antidepressant response (choice D) provides the strongest pharmacological evidence that these are genuinely separate therapeutic mechanisms rather than the same process applied to different conditions. Study tip: Remember that when the same drug produces different effects with different timelines or dose requirements, this usually indicates distinct mechanisms of action - a concept that appears frequently in psychopharmacology questions.

Question 5

A patient taking high-dose venlafaxine for neuropathic pain decides to stop the medication abruptly because they feel better. Two days later, they call the clinic complaining of intense dizziness, anxiety, insomnia, and a sensation of 'electric shocks' in their head. This syndrome is best explained by which neuropharmacological concept?

  1. Acute withdrawal due to the medication's short elimination half-life. (correct answer)
  2. Downregulation of postsynaptic serotonin and norepinephrine receptors.
  3. Rebound excitotoxicity from unblocked NMDA receptors.
  4. Accumulation of a toxic metabolite with a long half-life.
Explanation: When you encounter questions about sudden medication discontinuation followed by rapid onset of symptoms, think about discontinuation syndrome and the pharmacokinetic properties that influence its severity. Venlafaxine has a notably short elimination half-life of approximately 5 hours (11 hours including its active metabolite). When stopped abruptly, plasma levels drop rapidly, leaving the CNS suddenly deprived of serotonin and norepinephrine reuptake inhibition it has adapted to. The "brain zaps" or electric shock sensations are classic hallmarks of SNRI discontinuation syndrome, appearing within 1-3 days due to this short half-life. Choice A is correct because the rapid onset and characteristic symptoms directly result from venlafaxine's quick elimination from the system. Choice B describes receptor downregulation, which is a chronic adaptive change that occurs during treatment, not the acute mechanism causing withdrawal symptoms. Choice C references NMDA receptor excitotoxicity, which is irrelevant here since venlafaxine doesn't significantly interact with glutamate systems. Choice D suggests toxic metabolite accumulation, but venlafaxine's metabolites aren't toxic, and withdrawal symptoms stem from absence of the drug, not presence of harmful compounds. The key insight is that medications with shorter half-lives (like venlafaxine, paroxetine) cause more severe discontinuation syndromes than those with longer half-lives (like fluoxetine). Remember: short half-life = higher discontinuation risk. Always taper SNRIs and SSRIs gradually, especially those eliminated quickly from the body.

Question 6

A 78-year-old female with trigeminal neuralgia, a history of myocardial infarction, glaucoma, and constipation is prescribed a new medication for her facial pain. Which of the following agents would be the most problematic choice for this patient, considering all of her comorbidities?

  1. Gabapentin
  2. Pregabalin
  3. Duloxetine
  4. Amitriptyline (correct answer)
Explanation: When evaluating medications for patients with multiple comorbidities, you need to consider how each drug's side effect profile interacts with existing conditions. This question tests your ability to identify contraindications and relative risks across different drug classes used for neuropathic pain. Amitriptyline (D) is the most problematic choice because tricyclic antidepressants have significant anticholinergic effects that directly worsen this patient's conditions. The anticholinergic properties can increase intraocular pressure, potentially precipitating an acute glaucoma attack in someone with existing glaucoma. Additionally, these effects cause decreased GI motility, severely worsening constipation. Tricyclics also have cardiotoxic effects including QT prolongation and arrhythmias, which pose serious risks in a patient with prior myocardial infarction. Gabapentin (A) is generally well-tolerated with minimal drug interactions and no significant anticholinergic effects, making it safer for this patient profile. Pregabalin (B) shares gabapentin's favorable safety profile regarding anticholinergic effects and cardiac risks, though it may cause some peripheral edema. Duloxetine (C), while an antidepressant, is an SNRI rather than a tricyclic and lacks the problematic anticholinergic effects that make amitriptyline dangerous. Remember that tricyclic antidepressants have a "dirty" pharmacology profile with multiple receptor interactions beyond their intended target. When you see elderly patients with glaucoma, constipation, or cardiac conditions, immediately flag tricyclics as potentially dangerous due to their anticholinergic and cardiotoxic effects. Always consider the complete side effect profile, not just efficacy.

Question 7

While both pregabalin and gabapentin bind to the α2-δ subunit of voltage-gated calcium channels, pregabalin exhibits certain pharmacokinetic advantages over gabapentin. Which of the following best describes a key pharmacokinetic difference that contributes to pregabalin's more predictable dose-response relationship?

  1. Pregabalin undergoes extensive hepatic metabolism via CYP3A4, resulting in a consistent first-pass effect.
  2. Pregabalin's absorption is dose-dependent and saturable, preventing toxic plasma concentrations at high doses.
  3. Pregabalin is absorbed via a high-capacity amino acid transporter, resulting in linear, dose-proportional absorption. (correct answer)
  4. Pregabalin has a higher degree of plasma protein binding, leading to a more stable free drug concentration.
Explanation: Gabapentin's absorption is mediated by the L-amino acid transporter system (LAT1) in the gut, which is saturable. This leads to non-linear, dose-disproportional absorption, meaning that as the dose of gabapentin increases, the fraction absorbed decreases. In contrast, pregabalin is absorbed by a different, high-capacity transport system that does not become saturated at therapeutic doses, resulting in linear and predictable dose-proportional absorption. This predictability simplifies dosing. Neither drug undergoes significant hepatic metabolism (A) or has significant plasma protein binding (D). (B) accurately describes gabapentin's absorption, not pregabalin's.

Question 8

A 72-year-old patient is being treated with nortriptyline for neuropathic pain. The patient reports significant benefit but is bothered by sedation and orthostatic hypotension. Which of the following properties of nortriptyline is most likely responsible for these two specific adverse effects?

  1. Antagonism of muscarinic cholinergic receptors.
  2. Inhibition of norepinephrine reuptake transporters.
  3. Antagonism of alpha-1 adrenergic and H1 histaminic receptors. (correct answer)
  4. Blockade of fast voltage-gated sodium channels.
Explanation: Orthostatic hypotension associated with TCAs is primarily due to the blockade of alpha-1 adrenergic receptors. Sedation is primarily caused by antagonism of central H1 histamine receptors. While TCAs have other actions, this option correctly links both reported side effects to their respective receptor-blocking properties. Muscarinic antagonism (A) causes dry mouth, constipation, and blurred vision. Norepinephrine reuptake inhibition (B) is part of the therapeutic effect and can sometimes cause tachycardia or hypertension. Sodium channel blockade (D) is linked to cardiotoxicity in overdose.

Question 9

A patient is being counseled on initiating therapy with gabapentin for neuropathic pain. Which statement accurately reflects the titration schedule and rationale for this medication?

  1. A high loading dose should be administered to achieve rapid analgesia, followed by a lower maintenance dose.
  2. The dose should be started low and titrated up slowly over days to weeks primarily to improve patient tolerability. (correct answer)
  3. The medication should be dosed once daily at bedtime due to its long half-life and sedative properties.
  4. Titration is necessary because the drug induces its own metabolism, requiring dose increases to maintain effect.
Explanation: Gabapentin must be initiated at a low dose (e.g., 100-300 mg) and titrated up gradually. The primary reason for this slow titration is to minimize CNS side effects, such as somnolence, dizziness, and ataxia, which are common at the beginning of therapy and can lead to non-adherence. A loading dose (A) would cause intolerable side effects. Gabapentin has a relatively short half-life (5-7 hours), requiring multiple daily doses (typically TID) (C). It does not induce its own metabolism (D).

Question 10

A patient experiences a witnessed generalized seizure after taking several tablets of a prescribed medication for neuropathic pain in a suicide attempt. On presentation to the emergency department, the EKG shows a QRS duration of 140 ms and a prominent R wave in lead aVR. Which medication is the most likely cause of this presentation?

  1. Pregabalin
  2. Duloxetine
  3. Gabapentin
  4. Amitriptyline (correct answer)
Explanation: The clinical presentation of seizures and characteristic EKG findings (QRS widening >100 ms, prominent R wave in aVR) is classic for a tricyclic antidepressant (TCA) overdose. The cardiotoxicity is due to blockade of fast sodium channels in the His-Purkinje system. Overdoses of gabapentin (C) and pregabalin (A) typically cause sedation, ataxia, and confusion, but are much less likely to cause life-threatening cardiotoxicity. Duloxetine (B) overdose can cause seizures and tachycardia but does not typically produce the characteristic QRS widening seen with TCAs.

Question 11

A patient with postherpetic neuralgia experiences partial relief with a maximum tolerated dose of pregabalin. The physician plans to add a second agent with a complementary mechanism of action. Which of the following describes the primary molecular action of pregabalin that a new agent should complement?

  1. Inhibition of norepinephrine and serotonin reuptake in the descending pain pathways.
  2. Blockade of voltage-gated sodium channels on the neuronal membrane, preventing action potential propagation.
  3. Binding to the α2-δ subunit of voltage-gated calcium channels, reducing neurotransmitter release. (correct answer)
  4. Antagonism of NMDA receptors in the dorsal horn, preventing central sensitization.
Explanation: Pregabalin's primary mechanism is binding to the α2-δ subunit of presynaptic N-type voltage-gated calcium channels. This reduces calcium influx, which in turn decreases the release of excitatory neurotransmitters like glutamate and substance P. To complement this presynaptic inhibitory mechanism, one might add an agent that works postsynaptically or modulates descending inhibitory pathways, like an SNRI (A) or TCA (which also has sodium channel blocking properties, B). (D) describes the mechanism of agents like ketamine, not the primary neuropathic pain agents in this category.

Question 12

A patient with fibromyalgia is prescribed pregabalin. After 4 weeks of titration to 150 mg twice daily, the patient reports significant dizziness and somnolence, which is interfering with daily activities. The patient has had a minimal reduction in pain. What is the most appropriate next step in managing this patient's therapy?

  1. Immediately discontinue pregabalin and switch to amitriptyline.
  2. Increase the pregabalin dose to 225 mg twice daily to achieve a better therapeutic effect.
  3. Reduce the pregabalin dose to 75 mg twice daily and reassess tolerability and efficacy. (correct answer)
  4. Add a low dose of duloxetine to augment the analgesic effects of pregabalin.
Explanation: The patient is experiencing dose-limiting side effects (dizziness, somnolence) with minimal efficacy. The most appropriate step is to reduce the dose to a previously tolerated level or a lower dose to see if the side effects resolve while maintaining some efficacy. Increasing the dose (B) would worsen the side effects. Abruptly stopping pregabalin (A) can cause withdrawal symptoms and is not ideal. Adding another CNS depressant like duloxetine (D) without first addressing the tolerability of the current agent could exacerbate the dizziness and somnolence.

Question 13

A patient experiences a witnessed generalized seizure after taking several tablets of a prescribed medication for neuropathic pain in a suicide attempt. On presentation to the emergency department, the EKG shows a QRS duration of 140 ms and a prominent R wave in lead aVR. Which medication is the most likely cause of this presentation?

  1. Pregabalin
  2. Duloxetine
  3. Gabapentin
  4. Amitriptyline (correct answer)
Explanation: The clinical presentation of seizures and characteristic EKG findings (QRS widening >100 ms, prominent R wave in aVR) is classic for a tricyclic antidepressant (TCA) overdose. The cardiotoxicity is due to blockade of fast sodium channels in the His-Purkinje system. Overdoses of gabapentin (C) and pregabalin (A) typically cause sedation, ataxia, and confusion, but are much less likely to cause life-threatening cardiotoxicity. Duloxetine (B) overdose can cause seizures and tachycardia but does not typically produce the characteristic QRS widening seen with TCAs.

Question 14

A patient with painful diabetic neuropathy and comorbid hypertension is managed with lisinopril and hydrochlorothiazide. The physician adds venlafaxine for the neuropathy. Which of the following parameters is most important to monitor after initiating venlafaxine in this patient?

  1. Serum creatinine
  2. Blood pressure (correct answer)
  3. Liver function tests
  4. Serum sodium
Explanation: Venlafaxine, an SNRI, can cause a dose-dependent increase in blood pressure due to its inhibition of norepinephrine reuptake. In a patient with pre-existing hypertension, it is crucial to monitor blood pressure closely after initiation and with each dose increase. While SNRIs can rarely cause hyponatremia (D) or hepatotoxicity (C), and renal function (A) is always good to monitor, the most common and predictable adverse effect related to the patient's comorbidity is an elevation in blood pressure.

Question 15

While both pregabalin and gabapentin bind to the α2-δ subunit of voltage-gated calcium channels, pregabalin exhibits certain pharmacokinetic advantages over gabapentin. Which of the following best describes a key pharmacokinetic difference that contributes to pregabalin's more predictable dose-response relationship?

  1. Pregabalin undergoes extensive hepatic metabolism via CYP3A4, resulting in a consistent first-pass effect.
  2. Pregabalin's absorption is dose-dependent and saturable, preventing toxic plasma concentrations at high doses.
  3. Pregabalin is absorbed via a high-capacity amino acid transporter, resulting in linear, dose-proportional absorption. (correct answer)
  4. Pregabalin has a higher degree of plasma protein binding, leading to a more stable free drug concentration.
Explanation: Gabapentin's absorption is mediated by the L-amino acid transporter system (LAT1) in the gut, which is saturable. This leads to non-linear, dose-disproportional absorption, meaning that as the dose of gabapentin increases, the fraction absorbed decreases. In contrast, pregabalin is absorbed by a different, high-capacity transport system that does not become saturated at therapeutic doses, resulting in linear and predictable dose-proportional absorption. This predictability simplifies dosing. Neither drug undergoes significant hepatic metabolism (A) or has significant plasma protein binding (D). (B) accurately describes gabapentin's absorption, not pregabalin's.

Question 16

A 78-year-old female with trigeminal neuralgia, a history of myocardial infarction, glaucoma, and constipation is prescribed a new medication for her facial pain. Which of the following agents would be the most problematic choice for this patient, considering all of her comorbidities?

  1. Gabapentin
  2. Pregabalin
  3. Duloxetine
  4. Amitriptyline (correct answer)
Explanation: When evaluating medications for patients with multiple comorbidities, you need to consider how each drug's side effect profile interacts with existing conditions. This question tests your ability to identify contraindications and relative risks across different drug classes used for neuropathic pain. Amitriptyline (D) is the most problematic choice because tricyclic antidepressants have significant anticholinergic effects that directly worsen this patient's conditions. The anticholinergic properties can increase intraocular pressure, potentially precipitating an acute glaucoma attack in someone with existing glaucoma. Additionally, these effects cause decreased GI motility, severely worsening constipation. Tricyclics also have cardiotoxic effects including QT prolongation and arrhythmias, which pose serious risks in a patient with prior myocardial infarction. Gabapentin (A) is generally well-tolerated with minimal drug interactions and no significant anticholinergic effects, making it safer for this patient profile. Pregabalin (B) shares gabapentin's favorable safety profile regarding anticholinergic effects and cardiac risks, though it may cause some peripheral edema. Duloxetine (C), while an antidepressant, is an SNRI rather than a tricyclic and lacks the problematic anticholinergic effects that make amitriptyline dangerous. Remember that tricyclic antidepressants have a "dirty" pharmacology profile with multiple receptor interactions beyond their intended target. When you see elderly patients with glaucoma, constipation, or cardiac conditions, immediately flag tricyclics as potentially dangerous due to their anticholinergic and cardiotoxic effects. Always consider the complete side effect profile, not just efficacy.

Question 17

A patient taking high-dose venlafaxine for neuropathic pain decides to stop the medication abruptly because they feel better. Two days later, they call the clinic complaining of intense dizziness, anxiety, insomnia, and a sensation of 'electric shocks' in their head. This syndrome is best explained by which neuropharmacological concept?

  1. Acute withdrawal due to the medication's short elimination half-life. (correct answer)
  2. Downregulation of postsynaptic serotonin and norepinephrine receptors.
  3. Rebound excitotoxicity from unblocked NMDA receptors.
  4. Accumulation of a toxic metabolite with a long half-life.
Explanation: When you encounter questions about sudden medication discontinuation followed by rapid onset of symptoms, think about discontinuation syndrome and the pharmacokinetic properties that influence its severity. Venlafaxine has a notably short elimination half-life of approximately 5 hours (11 hours including its active metabolite). When stopped abruptly, plasma levels drop rapidly, leaving the CNS suddenly deprived of serotonin and norepinephrine reuptake inhibition it has adapted to. The "brain zaps" or electric shock sensations are classic hallmarks of SNRI discontinuation syndrome, appearing within 1-3 days due to this short half-life. Choice A is correct because the rapid onset and characteristic symptoms directly result from venlafaxine's quick elimination from the system. Choice B describes receptor downregulation, which is a chronic adaptive change that occurs during treatment, not the acute mechanism causing withdrawal symptoms. Choice C references NMDA receptor excitotoxicity, which is irrelevant here since venlafaxine doesn't significantly interact with glutamate systems. Choice D suggests toxic metabolite accumulation, but venlafaxine's metabolites aren't toxic, and withdrawal symptoms stem from absence of the drug, not presence of harmful compounds. The key insight is that medications with shorter half-lives (like venlafaxine, paroxetine) cause more severe discontinuation syndromes than those with longer half-lives (like fluoxetine). Remember: short half-life = higher discontinuation risk. Always taper SNRIs and SSRIs gradually, especially those eliminated quickly from the body.

Question 18

A patient with diabetic neuropathy and comorbid anxiety is being considered for treatment. Which of the following agents offers an evidence-based benefit for both conditions through a single mechanism of action?

  1. Venlafaxine, by inhibiting the reuptake of serotonin and norepinephrine. (correct answer)
  2. Pregabalin, by reducing the release of both glutamate and norepinephrine.
  3. Amitriptyline, by blocking muscarinic receptors and sodium channels.
  4. Gabapentin, by directly agonizing GABA-B receptors in the amygdala and spinal cord.
Explanation: When you encounter questions about dual-indication medications, focus on identifying drugs with well-established mechanisms that address both conditions through the same pathway. This tests your understanding of how pharmacological mechanisms can provide therapeutic benefits across different disease states. Venlafaxine (A) is correct because it's a serotonin-norepinephrine reuptake inhibitor (SNRI) with robust evidence for treating both diabetic neuropathy and anxiety through this single mechanism. The enhanced norepinephrine signaling modulates descending pain pathways to reduce neuropathic pain, while increased serotonin and norepinephrine availability treats anxiety. This dual benefit through one mechanism makes it an ideal choice for comorbid conditions. Pregabalin (B) is wrong because while it does treat both conditions effectively, it doesn't reduce norepinephrine release—it actually blocks voltage-gated calcium channels to decrease excitatory neurotransmitter release, including glutamate. The mechanism described is inaccurate. Amitriptyline (C) is incorrect because although it can help both conditions, it works through multiple mechanisms (not a single one as the question specifies). Its benefits come from various actions including norepinephrine reuptake inhibition, sodium channel blockade, and anticholinergic effects—not just the two mechanisms listed. Gabapentin (D) is wrong on multiple levels. While it treats neuropathic pain, it has limited evidence for anxiety disorders. Additionally, it doesn't directly agonize GABA-B receptors—it binds to voltage-gated calcium channel subunits. Remember: SNRIs like venlafaxine and duloxetine are your go-to dual-indication drugs for neuropathic pain plus mood/anxiety disorders. Focus on learning drugs with clear, single mechanisms that provide multiple therapeutic benefits.

Question 19

While both TCAs and SNRIs inhibit the reuptake of norepinephrine, a key mechanistic distinction of TCAs that contributes significantly to their adverse effect profile but not their primary analgesic effect is their additional action as...

  1. agonists at presynaptic alpha-2 adrenergic receptors.
  2. antagonists at various receptors, including muscarinic, histaminic, and adrenergic. (correct answer)
  3. inhibitors of the voltage-gated α2-δ calcium channel subunit.
  4. modulators of intracellular signaling via G-protein-coupled inward-rectifier potassium (GIRK) channels.
Explanation: A major difference between TCAs and SNRIs is that TCAs are 'dirtier' drugs, meaning they interact with many receptor types beyond the norepinephrine and serotonin transporters. Their antagonism of muscarinic cholinergic receptors (causing dry mouth, constipation), H1 histamine receptors (causing sedation, weight gain), and alpha-1 adrenergic receptors (causing orthostatic hypotension) accounts for a large portion of their side-effect burden. SNRIs are much more selective for the reuptake transporters and have minimal affinity for these other receptors, giving them a more favorable side-effect profile.

Question 20

A 45-year-old male is treated with desipramine for chronic neuropathic back pain. He is also taking paroxetine for major depressive disorder. He presents with confusion, fever, and muscle rigidity. The co-administration of these two agents creates a risk for which of the following?

  1. Markedly elevated desipramine levels due to inhibition of its metabolism. (correct answer)
  2. An exaggerated anticholinergic response due to additive muscarinic blockade.
  3. Reduced efficacy of desipramine due to induction of its metabolism.
  4. A hypertensive crisis due to a tyramine-like reaction.
Explanation: When you encounter drug interaction questions involving antidepressants, focus on the cytochrome P450 enzyme system and how different medications can inhibit or induce each other's metabolism. The patient's symptoms—confusion, fever, and muscle rigidity—suggest elevated tricyclic antidepressant levels causing toxicity. Desipramine, a tricyclic antidepressant, is metabolized primarily by CYP2D6. Paroxetine is a potent CYP2D6 inhibitor, meaning it blocks the enzyme responsible for breaking down desipramine. When paroxetine inhibits CYP2D6, desipramine accumulates to toxic levels, producing the neurological and autonomic symptoms described. Answer A correctly identifies this mechanism: paroxetine's inhibition of desipramine metabolism leads to markedly elevated drug levels and toxicity. Answer B is incorrect because while both drugs have anticholinergic effects, the primary concern here isn't additive anticholinergic toxicity but rather elevated desipramine levels from metabolic inhibition. The symptoms described are more consistent with tricyclic toxicity than pure anticholinergic effects. Answer C is wrong because paroxetine inhibits rather than induces CYP2D6. Enzyme induction would decrease desipramine levels and reduce efficacy, which contradicts the patient's toxic presentation. Answer D is incorrect because tyramine reactions occur with MAO inhibitors and tyramine-containing foods, not with this drug combination. Neither paroxetine nor desipramine is an MAO inhibitor. Remember this pattern: SSRIs like paroxetine and fluoxetine are potent CYP2D6 inhibitors and frequently cause clinically significant interactions with tricyclic antidepressants, requiring dose adjustments or alternative medications.